Smarter leaders trust GlobalData

Data Insights Innovation in pharma: anti-IL monoclonal antibodies

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

Regeneron Pharmaceuticals Inc

Zoetis Inc

Grifols SA

Acorda Therapeutics Inc

View all

However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilizing and reaching maturity.

Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.

80+ innovations will shape the pharmaceutical industry

According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 730,000 patents, there are 80+ innovation areas that will shape the future of the industry.

Within the emerging innovation stage, engineered multi-specific antibodies, tyrosine kinase inhibitors, and mutant DNA polymerases are disruptive technologies that are in the early stages of application and should be tracked closely. Peptide pharmacophores, antibody-drug conjugates, and neuroprotective drugs are some of the accelerating innovation areas where adoption has been steadily increasing. Among maturing innovation areas are amyloid precursor targeted therapies and modified vector HIV-1 vaccines, which are now well established in the industry.

Innovation S-curve for the pharmaceutical industry

Anti-IL monoclonal antibodies is a key innovation area in the pharmaceutical industry

Anti- interleukin (IL) humanized monoclonal antibodies are a type of biopharmaceutical drug that specifically target and bind to IL molecules – a type of cytokine – in the body, preventing their activity and reducing inflammation and immune responses associated with various autoimmune disorders, inflammatory diseases and cancer.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 435+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of anti-IL monoclonal antibodies.

Key players in the anti-IL monoclonal antibodies space – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.

‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.

Patent volumes related to anti-IL monoclonal antibodies space

Immatics is one of the leading patent filers in anti-IL monoclonal antibodies (mAbs). The company’s TCER platform is used to develop bi-specific antibodies. By using this technique, the company develops anti-IL mAbs for the treatment of various diseases.

In terms of application diversity, Iovance Biotherapeutics leads the pack, while OncoTherapy Science and Immatics stood in the second and third positions, respectively.

By means of geographic reach, Stryker held the top position, followed by Zoetis and Acorda Therapeutics.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.